TrialBMC cancer2022

Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial.

Houpu Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.